Funding Rounds
Enterome

Enterome Series D (2017, $34M)

Enterome

Cutting-edge immunomodulatory drugs for the treatment of cancer and immune diseases.

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →